TB-500

TB-500 is a synthetic version of Thymosin Beta-4, a 43-amino-acid protein originally isolated from the thymus gland. Thymosin Beta-4 is one of the most abundant intracellular proteins and is expressed in virtually every tissue type, with particularly high concentrations in wound fluid, platelets, and cells undergoing migration. TB-500 replicates the active region of the full-length protein — specifically the actin-binding domain responsible for its regenerative properties — making it the research-optimized fragment of a naturally ubiquitous healing molecule.

TB-500 functions primarily through its interaction with actin, the structural protein that forms the cytoskeleton of every cell. By sequestering G-actin monomers and promoting their polymerization into F-actin filaments, TB-500 directly facilitates cell migration — the physical movement of cells into damaged tissue. This is the foundational mechanism of wound repair. Beyond cytoskeletal modulation, TB-500 promotes angiogenesis (new blood vessel formation) by upregulating vascular endothelial growth factor (VEGF), reduces inflammation through downregulation of pro-inflammatory cytokines including IL-1beta, TNF-alpha, and IL-6, and has demonstrated anti-fibrotic properties that may reduce scar tissue formation.

The research literature positions TB-500 as a systemic tissue repair agent. Unlike BPC-157, which acts preferentially at local injection sites, TB-500 distributes throughout the body after administration and exerts effects wherever tissue damage or inflammation exists. Studies have demonstrated accelerated healing in cardiac tissue following ischemic injury, improved dermal wound closure rates, reduced inflammation in musculoskeletal injuries, and enhanced recovery of damaged neural tissue. Researchers have also noted improvements in hair regrowth models, suggesting effects on dermal stem cell populations.

TB-500 is best suited for researchers investigating systemic recovery from musculoskeletal injuries, post-surgical healing, chronic inflammatory conditions, and cardiac tissue repair. It is the preferred companion to BPC-157 in healing stacks: TB-500 provides the broad, systemic regenerative signal while BPC-157 concentrates healing activity at the local level. This pairing is one of the most widely referenced combinations in the peptide research community.

Each 5mg vial should be reconstituted with 1-2ml bacteriostatic water. TB-500 has a notably long half-life of approximately 14 days, which allows for less frequent dosing compared to most peptides — typically twice-weekly subcutaneous injection. Researchers commonly use a loading phase of 5-10mg per week for the first 4-6 weeks, followed by a maintenance phase of 2-5mg per week. Reconstituted solution should be stored at 2-8C. TB-500 can be injected subcutaneously at any site; its systemic distribution means injection location is less critical than with site-specific compounds.